These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27198690)

  • 21. Peripheral Endovascular Interventions in the Era of Precision Medicine: Tying Wire, Drug, and Device Selection to Plaque Morphology.
    Roy T; Dueck AD; Wright GA
    J Endovasc Ther; 2016 Oct; 23(5):751-61. PubMed ID: 27328912
    [No Abstract]   [Full Text] [Related]  

  • 22. Postapproval outcomes of juxtarenal aortic aneurysms treated with the Zenith fenestrated endovascular graft.
    Vemuri C; Oderich GS; Lee JT; Farber MA; Fajardo A; Woo EY; Cayne N; Sanchez LA
    J Vasc Surg; 2014 Aug; 60(2):295-300. PubMed ID: 24680241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conformable GORE TAG thoracic endoprosthesis.
    Morasch MD
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):949-54. PubMed ID: 24931379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale for the use of bioresorbable vascular scaffolds. Why bioresorbable technology is the future of endovascular therapeutics.
    Ribichini F
    Minerva Cardioangiol; 2016 Aug; 64(4):399-403. PubMed ID: 27228487
    [No Abstract]   [Full Text] [Related]  

  • 25. First US experience following FDA approval of the ABBOTT vascular bioresorbable vascular scaffold for the treatment of coronary artery disease.
    Rizik DG; Shah MG; Burke RF
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):899-901. PubMed ID: 27545489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Moving into the paravisceral aorta using fenestrated and branched endografts.
    Farber MA; Vallabhaneni R
    Semin Vasc Surg; 2012 Dec; 25(4):193-9. PubMed ID: 23206565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Observations from the recent FDA Circulatory System Devices Panel meeting on bioresorbable vascular scaffolds.
    Serruys PW
    EuroIntervention; 2016 Apr; 11(14):e1569-70. PubMed ID: 27056130
    [No Abstract]   [Full Text] [Related]  

  • 28. An emerging medical giant.
    King SB
    JACC Cardiovasc Interv; 2013 Apr; 6(4):429-30. PubMed ID: 23597615
    [No Abstract]   [Full Text] [Related]  

  • 29. Assessment of Clinical Trial Evidence for High-Risk Cardiovascular Devices Approved Under the Food and Drug Administration Priority Review Program.
    Jones LC; Dhruva SS; Redberg RF
    JAMA Intern Med; 2018 Oct; 178(10):1418-1420. PubMed ID: 30178044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Food and Drug Administration-approved endovascular repair devices for abdominal aortic aneurysms: a review.
    Tan JW; Yeo KK; Laird JR
    J Vasc Interv Radiol; 2008 Jun; 19(6 Suppl):S9-S17. PubMed ID: 18502391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug delivering technology for endovascular management of infrainguinal peripheral artery disease.
    Sarode K; Spelber DA; Bhatt DL; Mohammad A; Prasad A; Brilakis ES; Banerjee S
    JACC Cardiovasc Interv; 2014 Aug; 7(8):827-39. PubMed ID: 25147028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endovascular aortoiliac aneurysm repair: surgical progress through new treatment paradigms and innovative endograft design.
    Buckley SD; Buckley CJ
    AORN J; 2014 Sep; 100(3):271-9. PubMed ID: 25172562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA Town Hall at CRT 2017: Current status and future endeavors in cardiovascular devices.
    Buchanan KD; Alraies MC; Waksman R
    Cardiovasc Revasc Med; 2017 Jun; 18(4):308-311. PubMed ID: 28577795
    [No Abstract]   [Full Text] [Related]  

  • 34. Evidence strength in FDA premarket approval of cardiovascular devices.
    Kong DF; Hasselblad V; Krucoff MW
    JAMA; 2010 Apr; 303(16):1599-600; author reply 1600-1. PubMed ID: 20424248
    [No Abstract]   [Full Text] [Related]  

  • 35. Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007.
    Kramer DB; Mallis E; Zuckerman BD; Zimmerman BA; Maisel WH
    Am J Ther; 2010; 17(1):2-7. PubMed ID: 20038828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synchron receives FDA approval to begin early feasibility study of their endovascular, brain-computer interface device.
    Han JJ
    Artif Organs; 2021 Oct; 45(10):1134-1135. PubMed ID: 34414575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advertising of therapies for cardiovascular patients.
    Foster MC
    Clin Cardiol; 1997 May; 20(5):506-7. PubMed ID: 9134288
    [No Abstract]   [Full Text] [Related]  

  • 38. The evolving options for endovascular repair of complex aortic aneurysms. Foreword.
    Oderich GS; Greenberg RK
    Perspect Vasc Surg Endovasc Ther; 2011 Sep; 23(3):145-8. PubMed ID: 22205653
    [No Abstract]   [Full Text] [Related]  

  • 39. Editors' commentary.
    Forbes TL; Ricco JB
    J Vasc Surg; 2011 Jul; 54(1):267-8. PubMed ID: 21722833
    [No Abstract]   [Full Text] [Related]  

  • 40. Invited commentary.
    Bush RL
    J Vasc Surg; 2010 Nov; 52(5):1146. PubMed ID: 21050986
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.